Comparison of the effects of metformin and glorenta on fatty liver in patients with type 2 diabetes

Comparison of the effects of Metformin and glorenta (Empagliflozin and linagliptin) on fatty liver of patients with type 2 diabetes in Ilam in 2021

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210922052550N1

Enrollment

Registered

2021-11-07

Start date

2021-11-11

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Fatty liver of type 2 diabetic patients. Condition 2: Fatty liver of type 2 diabetic patients. Condition 3: Fatty liver of type 2 diabetic patients. Condition 4: Fatty liver of type 2 diabetic patients. Fatty (change of) liver, not elsewhere classified Metabolic syndrome Nonalcoholic steatohepatitis (NASH) Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Control group: will receive metformin tablets, daily use (once) ?, drug dose: 500 mg, duration of use 12 weeks, number: 90 tablets, how to use: with breakfast, number of use: one daily

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Willingness to cooperate and complete the informed consent form by the patient Patients over 18 years of age No pregnancy and lactation Do not drink alcohol

Exclusion criteria

Exclusion criteria: Kidney disease Drugs sensitivity Diabetic ketoacidosis Exfoliative dermatitis and angioedema

Design outcomes

Primary

Measure	Time frame
Determination and comparison of serum levels of alanine aminotransferase at the beginning and end of the study. Timepoint: Measurement of serum levels of alanine aminotransferase at the beginning of the study and three month later. Method of measurement: Serum levels of Alanine aminotransferase will be measured by a reagent laboratory and results will be obtained.	—

Secondary

Measure	Time frame
Determining and comparing the ratio of abdominal circumference to hip circumference at the beginning and end of the study. Timepoint: Measure the ratio of abdominal circumference to hip circumference at the beginning of the study and three month later. Method of measurement: Measure the ratio of abdominal circumference to hip circumference using an inelastic meter.;Determining and comparing ultrasound findings at the beginning and end of the study. Timepoint: Perform ultrasound at the beginning of the study and three months later. Method of measurement: Perform ultrasound by the selected ultrasound center and get the results.	—

Measure

Time frame

Determining and comparing the ratio of abdominal circumference to hip circumference at the beginning and end of the study. Timepoint: Measure the ratio of abdominal circumference to hip circumference at the beginning of the study and three month later. Method of measurement: Measure the ratio of abdominal circumference to hip circumference using an inelastic meter.;Determining and comparing ultrasound findings at the beginning and end of the study. Timepoint: Perform ultrasound at the beginning of the study and three months later. Method of measurement: Perform ultrasound by the selected ultrasound center and get the results.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Shabazi

Ilam University of Medical Sciences

Shahbazi-sh@medilam.ac.ir+98 84 3333 8228

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026